Filing Details
- Accession Number:
- 0001181431-13-004933
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-01-25 20:43:23
- Reporting Period:
- 2013-01-23
- Filing Date:
- 2013-01-25
- Accepted Time:
- 2013-01-25 20:43:23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1401923 | Map Pharmaceuticals Inc. | MAPP | Pharmaceutical Preparations (2834) | 200507047 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1413822 | Anastasios Gianakakos | 2400 Bayshore Parkway, Suite 200 Mountain View CA 94043 | Svp, Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-01-23 | 30,000 | $10.37 | 44,330 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-01-23 | 30,000 | $24.76 | 14,330 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-01-23 | 30,000 | $0.00 | 30,000 | $10.37 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
57,244 | 2019-02-01 | No | 4 | M | Direct |
Footnotes
- The transaction was made pursuant to a 10b5-1 trading plan in effect at the time of the transaction.
- The shares subject to this stock option become exercisable as they vest. Twenty-five percent (25%) of the total number of shares vest and become exercisable on the first anniversary of the grant date. Thereafter, the remaining shares vest and become exercisable cumulatively in equal monthly installments over the following thirty-six (36) months so that all shares become vested and fully exercisable on the fourth anniversary of the grant date.